A new research has recognized vitamin E as a treatment, which can provide respite to several of the predicted 10 million Americans who suffer from the most prevalent chronic liver disease.

Study Author, Dr. Arun J. Sanyal, Chairman of the Division of Gastroenterology, Hepatology and Nutrition at Virginia Commonwealth University said, "This clearly shows that vitamin E is effective for treatment of patients with nonalcoholic steatohepatitis who don't have active diabetes".

A report on the experiment came out in the April 28 online edition of the New England Journal of Medicine.

Sanyal remarked that another drug checked in the trial, the diabetes medication pioglitazone (Actos), offered some relief, but failed to meet the standards set in the study.

The experiment did not analyze the two treatments nose–to-nose. Rather, each was trialed against a placebo, an immobile substance. Sanyal said that these treatments were preferred for the experiment as older studies signified that insulin resistance was a significant facet of the condition that is less formally dubbed nonalcoholic fatty liver disease, whereas oxidative stress also plays a significant function.

While, actos decreases insulin resistance, vitamin E is an antioxidant.

Sanyal said that the study points out that probably 43% of people with the condition who are not diabetic, will gain by taking doses of vitamin E on a daily basis.

Whilst some drugs have shown promise in initial experiments, there is no drug which has gained approval from the U. S. Food and Drug Administration for treatment of nonalcoholic fatty liver disease.